Pheruza Tarapore

Research Assistant Professor

Division: Toxicology

Phone: 513-558-5148
Location: 338 Kettering Lab
PubMed Articles
Google Scholar Articles

Print this CV

Dr. Tarapore’s research interest focuses on finding effective RNA therapies to target advanced cancers, and to develop more sensitive and specific bio-imaging agents. Our studies are aimed at developing a RNA aptamer based approach for treating prostate and ovarian cancers. This involves development of RNA vehicles to deliver pro-apoptotic microRNA and siRNA targeting pro-survival genes, to specific tissues. The RNA vehicles consist of the relatively non-immunogenic and stable RNA aptamers specific for prostate or ovarian cancer cells. Dr. Tarapore is also developing various strategies to engineer the delivery vehicle and couple it with the therapeutic components to increase efficiency of delivery.

Related News:

  • 07/17/2015: Pheruza Tarapore PI in Cancer Center Retreat Grant
  • 03/27/2015: U.S. Department of Defense Funds Metastatic Prostate Cancer Research
  • 03/03/2014: BPA Linked to Prostate Cancer Study Shows
  • 08/29/2013: Researchers Identify Key Protein's Role in Cancer Development

  • Grants

    07/01/2002-06/30/2003. American Cancer Society – Ohio Chapter. Functional Interaction Between P53 and BRCA1in Regulation of Centrosome Duplicaiton in Breast Cancer Cells, PI, Closed.

    W81XWH-10-1-036705/15/2010-05/14/2014. Department of the Army Medical Research and Materiel Command. Targeted Delivery of Therapeutic RNA into Prostate Cancers – Grant, PI, Active.

    VA IPA – Tarapore04/01/2013-03/31/2014. Department of Veterans Affairs. Intergovernmental Personnel Act Agreement – Tarapore, PI, Active.

    2013-2014. Center for Environmental Genetics. Next Generation Biomedical Investigator – Grant, PI, Completed.

    2013-2014. Center for Environmental Genetics. Pilot Project Program Mentee/Mentor Award: Reprograming of DNA methylome in the testis by high fat diet and bisphenol A – Grant, PI, Completed.

    2012-12-2013. University of Cincinnati Medical Center. Provost’s Pilot Research Program Award: Detecting Ovarian Cancers with Tissue-Specific MRI Contrast Agents – Grant, PI, Completed.

    NIH/K22 ES024457-012014-2017. NIH/NIEHS. Chronic Exposure to Bisphenol A increase susceptibility to prostate cancer. – Grant, PI, Pending.

    2014-2015. Center for Environmental Genetics. Pilot Projects Grant Program – Grant, Pending.

    W81XWH-10-1-036705/15/2010-05/14/2014. Department of the Army Medical Research and Materiel Command. Targeted Delivery of Therapeutic RNA into Prostate Cancers, PI, Closed.

    Selected Publications

    Tarapore, P., Ying, J., Ouyang, B., Burke, B., Bracken, B., & Ho, S. (2014). Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro.. PloS One, 9 (3), e90332. doi:10.1371/journal.pone.0090332

    Lee, M., Ho, S., Tarapore, P., Chung, I., & Leung, Y. (2013). Estrogen receptor ? isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.. Neoplasia (New York, N.Y.), 15 (11), 1262-71.

    Lee, M., Leung, Y., Chung, I., Tarapore, P., & Ho, S. (2013). Estrogen receptor ? (ER?1) transactivation is differentially modulated by the transcriptional coregulator Tip60 in a cis-acting element-dependent manner.. The Journal of Biological Chemistry, 288 (35), 25038-52. doi:10.1074/jbc.M113.476952

    Smithrud, D. B., Wang, X., Tarapore, P., & Ho, S. (2013). Crown Ether Host-Rotaxanes as Cytotoxic Agents.. ACS Medicinal Chemistry Letters, 4 (1), 27-31. doi:10.1021/ml3003204

    Isaac, J., Tarapore, P., Zhang, X., Lam, Y., & Ho, S. (2012). Site-specific S-nitrosylation of integrin ?6 increases the extent of prostate cancer cell migration by enhancing integrin ?1 association and weakening adherence to laminin-1.. Biochemistry, 51 (48), 9689-97. doi:10.1021/bi3012324

    Tarapore, P., Hanashiro, K., & Fukasawa, K. (2012). Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation.. Cell Cycle (Georgetown, Tex.), 11 (15), 2931-46. doi:10.4161/cc.21396

    Leung, Y., Lee, M., Lam, H., Tarapore, P., & Ho, S. (2012). Estrogen receptor-beta and breast cancer: translating biology into clinical practice.. Steroids, 77 (7), 727-37. doi:10.1016/j.steroids.2012.03.008

    Ho, S., Johnson, A., Tarapore, P., Janakiram, V., Zhang, X., & Leung, Y. (2012). Environmental epigenetics and its implication on disease risk and health outcomes.. ILAR Journal / National Research Council, Institute of Laboratory Animal Resources, 53 (3-4), 289-305. doi:10.1093/ilar.53.3-4.289

    Tarapore, P., Shu, Y., Guo, P., & Ho, S. (2011). Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers.. Molecular Therapy : the Journal of the American Society of Gene Therapy, 19 (2), 386-94. doi:10.1038/mt.2010.243

    Shinmura, K., Bennett, R. A., Tarapore, P., & Fukasawa, K. (2007). Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication.. Oncogene, 26 (20), 2939-44. doi:10.1038/sj.onc.1210085

    Tarapore, P., Shinmura, K., Suzuki, H., Tokuyama, Y., Kim, S., Mayeda, A., & Fukasawa, K. (2006). Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing.. FEBS Letters, 580 (2), 399-409. doi:10.1016/j.febslet.2005.12.022

    Shinmura, K., Tarapore, P., Tokuyama, Y., George, K. R., & Fukasawa, K. (2005). Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity.. FEBS Letters, 579 (29), 6621-34. doi:10.1016/j.febslet.2005.10.057

    Mayhew, C. N., Bosco, E. E., Fox, S. R., Okaya, T., Tarapore, P., Schwemberger, S. J., Babcock, G. F., Lentsch, A. B., Fukasawa, K., & Knudsen, E. S. (2005). Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy.. Cancer Research, 65 (11), 4568-77. doi:10.1158/0008-5472.CAN-04-4221

    Tarapore, P., & Fukasawa, K. (2002). Loss of p53 and centrosome hyperamplification.. Oncogene, 21 (40), 6234-40. doi:10.1038/sj.onc.1205707

    Tarapore, P., Okuda, M., & Fukasawa, K. (2002). A mammalian in vitro centriole duplication system: evidence for involvement of CDK2/cyclin E and nucleophosmin/B23 in centrosome duplication.. Cell Cycle (Georgetown, Tex.), 1 (1), 75-81.

    Tarapore, P., Tokuyama, Y., Horn, H. F., & Fukasawa, K. (2001). Difference in the centrosome duplication regulatory activity among p53 ‘hot spot’ mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53.. Oncogene, 20 (47), 6851-63. doi:10.1038/sj.onc.1204848

    Tokuyama, Y., Horn, H. F., Kawamura, K., Tarapore, P., & Fukasawa, K. (2001). Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication.. The Journal of Biological Chemistry, 276 (24), 21529-37. doi:10.1074/jbc.M100014200

    Tarapore, P., Horn, H. F., Tokuyama, Y., & Fukasawa, K. (2001). Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway.. Oncogene, 20 (25), 3173-84. doi:10.1038/sj.onc.1204424

    Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P. K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., & Fukasawa, K. (2000). Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.. Cell, 103 (1), 127-40.

    Mussman, J. G., Horn, H. F., Carroll, P. E., Okuda, M., Tarapore, P., Donehower, L. A., & Fukasawa, K. (2000). Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression.. Oncogene, 19 (13), 1635-46. doi:10.1038/sj.onc.1203460

    Tarapore, P., & Fukasawa, K. (2000). p53 mutation and mitotic infidelity.. Cancer Investigation, 18 (2), 148-55.

    Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y. Q., Tarapore, P., & Fukasawa, K. (1999). Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression.. Oncogene, 18 (11), 1935-44. doi:10.1038/sj.onc.1202515

    Tarapore, P., Richmond, C., Zheng, G., Cohen, S. B., Kelder, B., Kopchick, J., Kruse, U., Sippel, A. E., Colmenares, C., & Stavnezer, E. (1997). DNA binding and transcriptional activation by the Ski oncoprotein mediated by interaction with NFI.. Nucleic Acids Research, 25 (19), 3895-903.